Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Background norepinephrine to reduce inotrope use after cardiac valve surgery
ChiCTR2300068949Phase 4Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of norepinephrine in Cardiac valve disease (VHD) and postoperative circulatory instability after cardiac surgery (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: intraoperative positive inotropic drug dosage and dosage of positive inotropic drug 24 hours after operation. Started Mar 2022; status: recruiting.
02
Drugs
norepinephrine
03
Conditions
Cardiac valve disease (VHD)postoperative circulatory instability after cardiac surgery
Beyond the preview
Go deeper on ChiCTR2300068949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068949.